NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 11 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 Net Profit Plunges 71% YoY to ₹11.58 Lakh Despite Revenue Growth to ₹14.18 Cr
Vineet Laboratories reported revenue from operations of ₹14.18 crore for Q2 FY27, down 18.6% YoY compared to ₹17.42 crore in Q2 FY26, but up 36.5% QoQ from ₹10.39 crore. Net profit dropped sharply by 71.1% YoY to ₹11.58 lakh from ₹40.10 lakh in Q2 FY26, largely impacted by high material costs (₹13.08 crore) and a ₹1.28 crore tax expense. For H1 FY27, the company generated negative operating cash flows of -₹8.63 crore, driven by heavy inventory buildup of ₹10.64 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுVineet Laboratories declared its unaudited financial results for the quarter and half-year ended September 30, 2026, alongside an unmodified limited review report.
ஏன் இது முக்கியம்The company's earnings remain highly volatile with persistent cash burn from operations (-₹8.63 cr in H1 FY27), putting pressure on its liquidity despite recent rights issue equity additions.
📅 குறுகிய காலம்Market sentiment may be dampened by the severe net margin contraction and negative operating cash flows.
📈 நீண்ட காலம்Structural recovery hinges on scaling API intermediate volumes, managing raw material volatility, and controlling inventory buildup.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flows (-₹8.63 cr in H1 FY27)
Significant working capital locked in inventories (₹74.73 cr)
Extremely low promoter holding (5.98%)
👀 கவனிக்க வேண்டியவை
Track inventory liquidation efficiency and working capital cycle in upcoming quarters, along with whether revenue can sustainably rebound towards historical levels.
Vineet Laboratories Q1 FY27 Net Profit at ₹1.51 Cr vs ₹0.87 Cr Loss YoY; Revenue Rises 39.7%
Vineet Laboratories reported its financial results for the quarter ended June 30, 2026, with revenue from operations growing 39.7% YoY to ₹10.39 Cr compared to ₹7.44 Cr in Q1 FY26, though down 45% sequentially from ₹18.89 Cr in Q4 FY26. The company turned profitable YoY, posting a net profit of ₹1.51 Cr versus a net loss of ₹0.87 Cr in Q1 FY26, aided by a deferred tax credit of ₹0.73 Cr. Profit before tax stood at ₹0.79 Cr compared to a pre-tax loss of ₹0.90 Cr in the year-ago quarter. Basic and diluted EPS for the quarter came in at ₹0.73, up from negative ₹0.94 in Q1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுVineet Laboratories reported its Q1 FY27 unaudited financial results, shifting from a YoY net loss to a net profit of ₹1.51 Cr.
ஏன் இது முக்கியம்A sustained return to profitability is crucial for the company, given its high debt-to-equity ratio of 0.99 and low promoter holding of 5.98%.
Revenue from operations (Q1 FY27): ₹1,039.32 LakhNet profit (Q1 FY27): ₹151.43 LakhPBT (Q1 FY27): ₹78.56 LakhBasic EPS: ₹0.73Q1 வருவாய் vs TTM வருவாய்: ~17.6%
📅 குறுகிய காலம்The turn from a YoY loss to a profit may support sentiment, though the sequential decline in revenue from ₹18.89 Cr in the preceding quarter could moderate optimism.
📈 நீண்ட காலம்Operating recovery remains sensitive to supply chain dependencies (80% Chinese raw material exposure) and pricing volatility in API intermediates.
⚠ அபாய எச்சரிக்கைகள்
Significantly delayed filing for the June 2026 quarter (approved on October 26, 2026)
Extremely low promoter holding at 5.98%
Bottom line was materially supported by a deferred tax credit of ₹0.73 Cr
👀 கவனிக்க வேண்டியவை
Monitor whether the company can maintain revenue momentum in subsequent quarters after the sharp sequential decline from ₹18.89 Cr in Q4 FY26, and track the proposed capital raise via rights issue.
Vineet Laboratories Limited announced the resignation of its statutory auditor, M/s. NSVR & Associates LLP, effective from the close of business hours on September 29, 2026. The auditor had completed the audit for FY2026 (issuing their report on August 25, 2026) out of an original 5-year tenure scheduled through the 11th AGM. The stated reasons for resignation are preoccupation with other assignments, time constraints, and cost considerations to the audit firm, with no reported disputes or information withholding.
உச்சம் நம்பிக்கை
என்ன மாறியதுStatutory Auditor NSVR & Associates LLP has resigned prematurely before completing their 5-year mandate.
ஏன் இது முக்கியம்Mid-term statutory auditor resignations require scrutiny regarding governance and continuity, although the auditor explicitly denied disputes or audit evidence issues.
Original appointment date: செப்டம்பர் 28, 2022Effective date of resignation: செப்டம்பர் 29, 2026Date of latest audit report issued: 25-08-2026
📅 குறுகிய காலம்May prompt market caution pending appointment of a new reputable audit firm before upcoming quarterly filings.
📈 நீண்ட காலம்Limited operational impact if a credible replacement auditor is onboarded smoothly without audit qualifications.
⚠ அபாய எச்சரிக்கைகள்
Mid-term auditor departure
Low promoter holding (5.98% as of June 2026)
👀 கவனிக்க வேண்டியவை
Track the upcoming Board and Audit Committee meetings for the recommendation and shareholder approval of a successor statutory auditor.
Vineet Labs Reports FY26 PBT of ₹1.28 Cr vs ₹20.78 Cr Loss; Equity Infusion of ₹29.08 Cr
Vineet Laboratories reported its audited standalone financial results for FY26, turning around with a Profit Before Tax (PBT) of ₹1.28 Cr compared to a loss of ₹20.78 Cr in FY25. The company completed a share issuance during the year, raising ₹29.08 Cr in net proceeds and expanding total equity to ₹45.60 Cr from ₹14.65 Cr. However, operating cash flow turned negative at -₹12.03 Cr (vs +₹11.49 Cr in FY25), driven primarily by working capital tie-up with inventory rising to ₹64.09 Cr. Cash and cash equivalents closed at ₹16.70 Cr at the end of FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுVineet Laboratories published its audited FY26 annual accounts with an unmodified audit opinion, showing a return to PBT profitability and balance sheet recapitalization via equity issue.
ஏன் இது முக்கியம்The ₹29.08 Cr equity raise bolsters the balance sheet and liquidity (cash of ₹16.70 Cr), helping offset past losses, though working capital cash absorption remains high.
FY26 Profit Before Tax: ₹128.27 லட்சம்FY25 Profit Before Tax: -₹2,077.55 LakhsProceeds from share issuance: ₹2,908.18 லட்சம்Operating cash flow FY26: -₹1,203.19 LakhsClosing cash & cash equivalents: ₹1,669.52 லட்சம்Total Equity (Net Worth): ₹4,560.19 லட்சம்
📅 குறுகிய காலம்Market sentiment should view the return to net profitability and reinforced equity cushion positively, though delayed annual filing timing remains a slight drag.
📈 நீண்ட காலம்Long-term viability will depend on stabilizing operating margins in API intermediates, reducing high China dependency, and converting inventory into cash flows.
⚠ அபாய எச்சரிக்கைகள்
Operating cash outflow of -₹12.03 Cr in FY26 due to working capital lock-up
Inventory increased 28.3% to ₹64.09 Cr, increasing working capital intensity
Delayed annual result filing in August 2026
👀 கவனிக்க வேண்டியவை
Track working capital unwinding and quarterly revenue consistency in upcoming FY27 quarters to verify sustained operational recovery.
MD Gaddam Venkata Ramana steps down; remains Non-Executive Director
Mr. Gaddam Venkata Ramana has ceased to be the Managing Director of Vineet Laboratories effective July 21, 2026. While he steps down from the executive role, he will continue to serve as a Non-Executive Director on the board. This leadership transition occurs at a critical time for the company, which is currently grappling with a TTM net loss of ‑Rs 10 Cr and a high Debt-to-Equity ratio of 3.07. Furthermore, promoter holding has seen a sharp decline from 15.89% in September 2025 to 5.98% by March 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Managing Director has transitioned from an executive leadership role to a Non-Executive Director position.
ஏன் இது முக்கியம்Leadership changes in micro-cap companies (Rs 73 Cr market cap) with high leverage and declining promoter skin-in-the-game often signal internal restructuring or potential shifts in control.
Shares held by outgoing MD: 4,71,000 யூனிட்கள்Promoter Holding (Mar 2026): 5.98%Debt-to-Equity Ratio: 3.07TTM Net Profit: ‑Rs 10 CrOperating Profit Margin: -9.3%
📅 குறுகிய காலம்The stock may remain volatile as the market assesses the impact of the MD's departure from executive duties amidst weak financial performance.
📈 நீண்ட காலம்The structural concern remains the company's high debt and 80% dependency on China for raw materials; leadership stability is crucial for navigating these risks.
⚠ அபாய எச்சரிக்கைகள்
High Debt-to-Equity ratio of 3.07
Significant decline in promoter holding (from 15.89% to 5.98%)
Negative operating margins and consistent losses
👀 கவனிக்க வேண்டியவை
Investors should monitor the appointment of a successor and observe if the leadership change leads to a strategy for debt reduction and operational turnaround, given the negative OPM of -9.3%.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Vineet Laboratories Defers FY26 Audited Financial Results; Company Secretary Resigns
Vineet Laboratories has postponed the consideration and approval of its audited standalone financial results for the quarter and year ended March 31, 2026. The deferment occurred because the Audit Committee did not recommend the results to the Board during the meeting held on May 30, 2026. Furthermore, the company announced the resignation of its Company Secretary and Compliance Officer. The trading window for dealing in the company's equity shares will remain closed until 48 hours after the results are eventually declared.
முக்கிய அம்சங்கள்
Audited financial results for the fiscal year ended March 31, 2026, have been officially deferred.The Board meeting held on May 30, 2026, failed to approve results as the Audit Committee did not recommend them.Resignation of the Company Secretary and Compliance Officer was formally communicated to the Board.Trading window remains closed for all designated persons until 48 hours post-result declaration.A revised date for the Audit Committee and Board Meeting will be intimated in due course.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the delay in reporting year-end results alongside the exit of a compliance officer can be a red flag for governance or accounting issues. Await the revised meeting date and the eventual financial disclosures to assess the company's health.
Vineet Laboratories Q3 FY26: Turnaround to ₹85 Lakh Profit; Revenue Down 13.5% YoY
Vineet Laboratories reported a significant turnaround in Q3 FY26, posting a net profit of ₹85.07 Lakhs compared to a net loss of ₹570.70 Lakhs in the same period last year. This recovery occurred despite a 13.5% year-on-year decline in revenue from operations, which stood at ₹1,564.83 Lakhs. The board also ratified advances for Quality Control and RO water equipment for its new facility, noting these were not specifically mentioned in the December 2025 Rights Issue Letter of Offer. For the nine-month period ending December 2025, the company has returned to profitability with a net profit of ₹38.56 Lakhs.
முக்கிய அம்சங்கள்
Net Profit of ₹85.07 Lakhs in Q3 FY26 vs a Net Loss of ₹570.70 Lakhs in Q3 FY25.Revenue from operations decreased to ₹1,564.83 Lakhs from ₹1,809.93 Lakhs YoY.Total expenses significantly reduced to ₹1,487.79 Lakhs from ₹2,380.59 Lakhs in the previous year's quarter.Earnings Per Share (EPS) improved to ₹0.92 from a negative ₹6.19 YoY.Board ratified equipment advances for the new production facility, deviating from the specific objects of the recent Rights Issue.
👀 கவனிக்க வேண்டியவை
While the turnaround to profitability is a strong positive, investors should monitor the declining revenue trend and the execution of the new production facility. Watch for whether the cost-cutting measures that led to this profit are sustainable in the long term.
Vineet Laboratories Gets Trading Approval for 99.87 Lakh Rights Issue Shares
Vineet Laboratories Limited has received final trading approvals from both BSE and NSE for 99,87,258 equity shares allotted under its recent Rights Issue. These shares, issued at a price of Rs. 30 each (Rs. 10 face value plus Rs. 20 premium), are set to commence trading on February 05, 2026. This announcement marks the successful completion of the fundraising process, providing liquidity to the newly issued shares. Investors should be aware that the total outstanding equity has increased, which may lead to dilution of earnings per share (EPS).
முக்கிய அம்சங்கள்
Received trading approval for 99,87,258 equity shares from BSE and NSE.Shares issued at Rs. 30 per share, including a premium of Rs. 20.Trading of the new shares is effective from Thursday, February 05, 2026.Distinctive numbers for the new shares range from 9219009 to 19206266.
👀 கவனிக்க வேண்டியவை
Shareholders who were allotted shares in the rights issue can now trade them on the exchanges. Monitor the stock for potential short-term price volatility as the new supply of shares enters the secondary market.
Vineet Laboratories Allots 99.87 Lakh Equity Shares via Rights Issue at Rs 30 Per Share
Vineet Laboratories has successfully completed its rights issue by allotting 99,87,258 equity shares at a price of Rs 30 per share (including a premium of Rs 20). This capital infusion has raised approximately Rs 29.96 crore for the company. Consequently, the total paid-up equity share capital has more than doubled, increasing from Rs 9.22 crore to Rs 19.21 crore. The allotment follows the terms set in the Letter of Offer dated December 17, 2025.
முக்கிய அம்சங்கள்
Allotment of 99,87,258 equity shares of face value Rs 10 each on a rights basis.Issue price fixed at Rs 30 per share, representing a total fundraise of approx Rs 29.96 crore.Total number of equity shares increased from 92,19,008 to 1,92,06,266 post-allotment.Paid-up share capital expanded from Rs 9,21,90,080 to Rs 19,20,62,660.The allotment was finalized in consultation with Bigshare Services Private Limited and BSE Limited.
👀 கவனிக்க வேண்டியவை
Investors should track the company's upcoming quarterly results to see how the newly raised capital is deployed for growth. While the capital infusion is positive, shareholders should be aware of the significant equity dilution as the share count has more than doubled.
Vineet Laboratories Extends Rights Issue Closing Date to January 30, 2026
Vineet Laboratories Limited has announced an extension of its ongoing Rights Issue timeline following a committee meeting on January 13, 2026. The last date for On-Market Renunciation has been moved to January 27, 2026, while the overall Issue Closing Date is now January 30, 2026. This extension is intended to provide more time for investors to participate in the fundraising process. Following the closure, the basis of allotment and listing of shares are scheduled for February 2 and February 3, 2026, respectively.
முக்கிய அம்சங்கள்
Last date for On-Market Renunciation of Rights Entitlements extended to January 27, 2026Rights Issue closing date officially extended to January 30, 2026Basis of Allotment and Allotment of Shares scheduled for February 2, 2026Listing of new Equity Shares on BSE and NSE expected by February 3, 2026
👀 கவனிக்க வேண்டியவை
Investors holding Rights Entitlements (REs) should ensure they either subscribe to the issue or sell their REs on the market by January 27 to avoid total value loss. Monitor the share price relative to the rights price to determine if subscription is financially viable.
Vineet Laboratories to Raise ₹29.97 Crore via Rights Issue at ₹30 Per Share
Vineet Laboratories Limited has submitted its Letter of Offer for a Rights Issue aiming to raise approximately ₹29.97 crore. The company will issue 99,87,258 equity shares at a price of ₹30 per share, which includes a premium of ₹20. The rights entitlement ratio is fixed at 13 shares for every 12 shares held by eligible shareholders as of the record date, December 23, 2025. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
முக்கிய அம்சங்கள்
Rights issue size of up to 99,87,258 shares aggregating to ₹29.97 CroresIssue price set at ₹30 per share (Face Value ₹10 + Premium ₹20)Rights entitlement ratio of 13:12 for shareholders as of December 23, 2025Subscription period opens on January 01, 2026, and closes on January 21, 2026On-market renunciation period ends on January 16, 2026
👀 கவனிக்க வேண்டியவை
Existing shareholders should monitor the market price relative to the ₹30 offer price and decide whether to subscribe, renounce, or sell their rights entitlements before the January 16 deadline.
Vineet Laboratories Announces ₹29.96 Cr Rights Issue; Record Date Dec 23, 2025
Vineet Laboratories has finalized the terms for its Rights Issue, aiming to raise approximately ₹29.96 crores by issuing 99,87,258 equity shares. The issue price is fixed at ₹30 per share, and the record date for determining eligible shareholders is December 23, 2025. The entitlement ratio is set at 13:12, which will significantly expand the company's equity base from 92.19 lakh shares to 1.92 crore shares upon full subscription. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
முக்கிய அம்சங்கள்
Rights Issue size of ₹29.96 crores involving 99,87,258 fully paid-up equity shares.Issue price set at ₹30 per share, including a premium of ₹20 per share.Entitlement ratio of 13 Rights Equity Shares for every 12 Equity Shares held as of the record date.Record date for eligibility is December 23, 2025; Issue period runs from Jan 1 to Jan 21, 2026.Post-issue equity capital to increase from 92,19,008 to 1,92,06,266 shares assuming full subscription.
👀 கவனிக்க வேண்டியவை
Investors should compare the current market price with the ₹30 issue price to determine if the rights offer is attractive. Existing shareholders must ensure they hold shares by the record date to receive entitlements, which they can either subscribe to or renounce.
Vineet Laboratories Receives BSE and NSE Approval for Rs 30 Crore Rights Issue
Vineet Laboratories Limited has secured in-principle approvals from both the National Stock Exchange (NSE) and BSE Limited to undertake a Rights Issue of fully paid-up equity shares. The company plans to raise up to Rs 30 Crores through this issue, offering shares with a face value of Rs 10 each. A board meeting is scheduled for December 17, 2025, to finalize the issue price, entitlement ratio, and record date. This capital infusion is expected to strengthen the company's balance sheet, though it will result in equity dilution for existing shareholders who do not participate.
முக்கிய அம்சங்கள்
Received in-principle approval from NSE on December 02, 2025, and BSE on December 16, 2025.The proposed Rights Issue aims to aggregate up to a total of Rs 30 Crores.Board meeting scheduled for December 17, 2025, to determine the issue price, entitlement ratio, and record date.The issue involves fully paid-up equity shares with a face value of Rs 10 each.
👀 கவனிக்க வேண்டியவை
Existing shareholders should wait for the announcement of the issue price and entitlement ratio to assess the discount offered compared to the market price. Investors should decide whether to subscribe to avoid dilution or sell their rights entitlements if the company allows renunciation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 17 for Price Finalization
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting from December 16 to December 17, 2025. The committee is scheduled to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the proposed capital raise. This delay is intended to facilitate the receipt of in-principle approval from BSE Limited. Investors should monitor the upcoming announcement as it will define the terms of equity dilution and the cost of new shares.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 16 to December 17, 2025.Committee to determine key modalities: Issue Price, Entitlement Ratio, and Record Date.Finalization is subject to receiving in-principle approval from BSE Limited.The initial meeting on December 16 lasted only 30 minutes (6:20 P.M. to 6:50 P.M.) before adjournment.
👀 கவனிக்க வேண்டியவை
Wait for the finalized terms on December 17 to evaluate the attractiveness of the rights issue price compared to the current market price. Assess the potential dilution effect once the entitlement ratio is announced.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 16, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 15, 2025, to December 16, 2025. The committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the upcoming rights issue. This adjournment is intended to allow time for the receipt of in-principle approval from the BSE. The meeting on December 15 lasted only 20 minutes before the decision to adjourn was made.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 15 to December 16, 2025Committee to determine Issue Price, Entitlement Ratio, and Record DateAdjournment pending in-principle approval from BSE LtdThe initial meeting on December 15 commenced at 7:00 PM and was adjourned at 7:20 PM
👀 கவனிக்க வேண்டியவை
Investors should wait for the adjourned meeting's outcome on December 16 to understand the pricing and dilution impact of the rights issue. Compare the announced issue price with the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 15, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 12, 2025, to Monday, December 15, 2025. The committee is set to finalize critical parameters of the proposed Rights Issue, including the Issue Price, Entitlement Ratio, and Record Date. This delay is primarily to await the in-principle approval from BSE Limited. The brief 30-minute session on Friday was a procedural commencement before the adjournment was announced.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 12 to December 15, 2025.Meeting will determine the Issue Price, Entitlement Ratio, and Record Date for the fundraise.Adjournment is necessitated by the pending in-principle approval from BSE Ltd.The original meeting commenced at 6:00 P.M. and was adjourned by 6:30 P.M. on the same day.Final modalities of the Rights Issue are subject to regulatory approvals and committee decisions.
👀 கவனிக்க வேண்டியவை
Investors should wait for the December 15 announcement to assess the Issue Price and Entitlement Ratio, which will determine the potential dilution and cost of participation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 12, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 11, 2025, to December 12, 2025. The committee is expected to finalize critical terms of the proposed fundraising, including the Issue Price, Entitlement Ratio, and Record Date. This delay is reportedly to facilitate the receipt of in-principle approval from BSE Ltd. The initial meeting on December 11 lasted only 20 minutes before the adjournment was called.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 11 to December 12, 2025Committee to determine Issue Price, Entitlement Ratio, and Record Date for the proposed Rights IssueFinalization is subject to receiving in-principle approval from BSE LtdThe meeting on December 11 commenced at 6:00 PM and was adjourned by 6:20 PM
👀 கவனிக்க வேண்டியவை
Investors should wait for the adjourned meeting's outcome on December 12 to evaluate the rights issue price and potential equity dilution.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 11, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, which was originally scheduled for December 9, 2025. The meeting is now set to reconvene on Thursday, December 11, 2025, to finalize the terms of the proposed fundraising. The committee is expected to determine the Issue Price, Entitlement Ratio, and Record Date during this session. This adjournment is necessary to await the in-principle approval from the BSE Limited.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 9 to December 11, 2025Meeting will finalize critical details including Issue Price and Entitlement RatioAdjournment is pending the receipt of in-principle approval from BSE LtdThe initial meeting on December 9 lasted only 20 minutes before adjournment
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming announcement on December 11 for specific rights issue terms. Evaluate the issue price relative to the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 9, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 6, 2025. The meeting is now rescheduled for Tuesday, December 9, 2025, as the company awaits in-principle approval from BSE Limited. During the upcoming session, the committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date. This fundraise is a significant event for the company's capital structure and liquidity.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned from December 6 to December 9, 2025Committee to decide on Issue Price, Entitlement Ratio, and Record DateAdjournment necessitated by pending In-principle approval from BSE LtdThe initial meeting on Dec 6 lasted only 30 minutes before being adjourned
👀 கவனிக்க வேண்டியவை
Investors should monitor the announcement on December 9 for the rights issue price and ratio to assess potential dilution and investment value.
Vineet Laboratories Rights Issue Committee Meeting Adjourned to Dec 6
Vineet Laboratories has adjourned its Rights Issue Committee meeting, which commenced on December 3, 2025, at 3:00 P.M., to December 6, 2025. The adjournment is to allow the committee to further consider the Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates, and other modalities of the proposed Rights Issue. This is pending receipt of in-principle approval from BSE Ltd. The initial meeting on December 3rd lasted from 3:00 P.M. to 4:00 P.M.
முக்கிய அம்சங்கள்
Rights Issue Committee meeting adjourned to December 6, 2025Initial meeting commenced on December 3, 2025, at 3.00 P.M.Initial meeting adjourned at 4.00 P.M.Considering Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of the Issue Price, Entitlement Ratio, Record date, and Issue dates on December 6, 2025. Evaluate the terms of the rights issue to determine whether to participate.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
